BMS, Apothecon Pay $515M To Settle Pricing Claims

Law360, New York (September 28, 2007, 12:00 AM EDT) -- Bristol-Myers Squibb Co. and its former generic subsidiary Apothecon BV have agreed to pay over $515 million to put to rest allegations of illegal drug pricing schemes, the U.S. Attorney for the District of Massachusetts said Friday.

The agreement settled a wide array of allegations against BMS and Apothecon, which accused the companies of promoting off-label use of antipsychotic drug Abilify, misreporting the price of antidepression drug Serzone, inflating prices of oncology and generic drugs and paying kickbacks to physicians and health care providers.

The government...
To view the full article, register now.